Bausch + Lomb, ‘Harnessing Momentum,’ Reports Fourth Quarter and Full-Year Revenue Growth

Published on February 19, 2026
VAUGHAN, Ontario—Eye health company Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced on Wednesday its fourth-quarter and full-year 2025 financial results and also provided 2026 guidance. The company reported revenue growth across all business segments in both the fourth quarter and for the full-year, including increases in vision care, surgical and pharmaceutical. During the fourth quarter, revenue increased by 10 percent (7 percent constant currency) to $1.405 billion from $1.280 billion in 2024. For the full year 2025, revenue grew by 6 percent (5 percent constant currency), reaching $5.101 billion compared with $4.791 billion in 2024.
Continue reading on website
Other news

FDA Approves Expanded Age Range for STAAR Surgical’s EVO ICL for Vision Correction

February 19, 2026
LAKE FOREST, Calif.—STAAR Surgical Company, a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian ICL for patients aged 21 to 60 years old, up from the previous approval for ages 21-45. This approva

Optimed partners with PMS providers for AI-supported referral tool

February 19, 2026
The ReferAI referral letter generation tool will be integrated into the practice management software of several providers